Search results
Results from the WOW.Com Content Network
5327 18791 Ensembl ENSG00000104368 ENSMUSG00000031538 UniProt P00750 P11214 RefSeq (mRNA) NM_033011 NM_000930 NM_000931 NM_001319189 NM_008872 RefSeq (protein) NP_000921 NP_001306118 NP_127509 NP_032898 Location (UCSC) Chr 8: 42.17 – 42.21 Mb Chr 8: 23.25 – 23.27 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Tissue-type plasminogen activator, short name tPA, is a protein that ...
A recent paper reports that the use of the drug tenecteplase, not yet approved for stroke treatment in the U.S., may lead to slightly better outcomes after a stroke than the commonly used alteplase.
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter. [5]
If symptoms last less than 24 hours, the stroke is a transient ischemic attack (TIA), also called a mini-stroke. [3] Hemorrhagic stroke may also be associated with a severe headache. [3] The symptoms of stroke can be permanent. [5] Long-term complications may include pneumonia and loss of bladder control. [3]
Stroke was added to the institute's mandate in the 1960s and in October 1968 the institute became the "National Institute of Neurological Diseases and Stroke". [24] Lasker was prompted to address the disease when Joseph P. Kennedy, father of then-President John F. Kennedy had one.
The structure of desmoteplase is similar to rt-PA (), but it does not contain the plasmin-sensitive cleavage site and the lysine-binding Kringle 2 domain.As a result, desmoteplase, in comparison to rt-PA, has high fibrin selectivity (100,000- v. 550-fold increase in catalytic activity), an absence of neurotoxicity, and no apparent negative effect on the blood–brain barrier.
The aim is the study of basic processes or potential therapeutic interventions in this disease, and the extension of the pathophysiological knowledge on and/or the improvement of medical treatment of human ischemic stroke. Ischemic stroke has a complex pathophysiology involving the interplay of many different cells and tissues such as neurons ...